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In both human and animals, in utero exposure to bisphenol A (BPA), an endocrine‐
disrupting chemical used in the production of plastics and epoxy resins, has been
shown to affect offspring reproductive and metabolic health during adult life. We
hypothesized that the effect of prenatal exposure to environmentally relevant doses
of BPA will be evident during fetal organogenesis and fetal/postnatal growth
trajectory. Pregnant ewes were administered BPA subcutaneously from 30 to 90 days
of gestation (term 147 days). Fetal organ weight, anthropometric measures,
maternal/fetal hormones and postnatal growth trajectory were measured in both
sexes. Gestational BPA administration resulted in higher accumulation in male than
female fetuses only at fetal day 65, with minimal impact on fetal/maternal steroid
milieu in both sexes at both time points. BPA‐treated male fetuses were heavier than
BPA‐treated female fetuses at fetal day 90 whereas this sex difference was not evi-
dent in the control group. At the organ level, liver weight was reduced in prenatal
BPA‐treated female fetuses, while heart and thyroid gland weights were increased
in BPA‐treated male fetuses relative to their sex‐matched control groups. Prenatal
BPA treatment also altered the postnatal growth trajectory in a sex‐specific manner.
Males grew slower during the early postnatal period and caught up later. Females, in
contrast, demonstrated the opposite growth trend. Prenatal BPA‐induced changes in
fetal organ differentiation and early life growth strongly implicate translational rele-
vance of in utero contributions to reproductive and metabolic defects previously
reported in adult female offspring.
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Intrauterine growth restriction (IUGR) is defined as birth weight
and/or length below the 10th percentile for gestational age secondary
to pathological restriction of fetal growth in utero (Kanaka‐
Gantenbein, Mastorakos, & Chrousos, 2003; Romo, Carceller, &wileyonlinelibrary.comTobajas, 2009). Incidence of IUGR in newborns of term pregnancies
ranges from 3% to 7% (Romo et al., 2009). IUGR followed by catch‐
up growth has been associated with chronic disease later in life,
including development of hypertension, impaired glucose tolerance,
type 2 diabetes and lipid abnormalities (Barker, 2004; Valsamakis,
Kanaka‐Gantenbein, Malamitsi‐Puchner, & Mastorakos, 2006)./journal/jat J Appl Toxicol. 2019;39:1516–1531.
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thirds are thought to be secondary to the adverse in utero environ-
ment (Valsamakis et al., 2006), including infection, disease states,
nutritional deficit/excess, maternal stress, endocrine abnormalities,
smoking or alcohol consumption, and exposure to environmental
chemicals (Hakim, Padmanabhan, & Vyas, 2017).
Programming of IUGR can be mediated by alteration of the feto‐
maternal hormonal milieu (Fowden, Giussani, & Forhead, 2006). As
steroid hormones orchestrate the dialogue between the uterine envi-
ronment and the fetus, inappropriate exposure to sex steroids, native
or environmental, can reprogram fetal development (Padmanabhan &
Veiga‐Lopez, 2011). Additionally, alterations in the gestational hor-
monal milieu can affect postnatal growth of the IUGR fetus leading
to catch‐up growth and permanent defects throughout the lifespan
of the individual. Such reprogramming of pre‐ and postnatal growth
has been linked to cardiometabolic and reproductive dysfunction
(Manikkam et al., 2004; Ong, Ahmed, Emmett, Preece, & Dunger,
2000; Ong & Dunger, 2002).
In recent years, endocrine‐disrupting chemicals (EDCs) that mimic
both estrogenic and androgenic actions have received considerable
attention relative to pregnancy outcomes and origin of human disease
(Veiga‐Lopez et al., 2015; Veiga‐Lopez, Pu, Gingrich, & Padmanabhan,
2018; Vom Saal, Nagel, Coe, Angle, & Taylor, 2012). One such ubiqui-
tous EDC with estrogenic and anti‐androgenic actions is bisphenol A
(BPA), used in the manufacture of plastics and epoxy resins used in
consumer products (vom Saal & Hughes, 2005). Worldwide, >7 billion
pounds of BPA are produced annually, generating 1 million dollars per
day in revenue for corporations (Erler & Novak, 2010). Human expo-
sure to BPA occurs through dust, air and water (Vandenberg, Hunt,
Myers, & Vom Saal, 2013). Regulatory agencies, such as the Environ-
mental Protection Agency, the Federal Drug Administration and the
National Toxicology Program have set different threshold doses of
BPA (50, 5 and 0.5 mg/kg/day, respectively (Beronius, Ruden,
Hakansson, & Hanberg, 2010; Erler & Novak, 2010) below which
adverse effects are not present. BPA has been found in maternal cir-
culation, amniotic fluid, adipose tissue, liver, placenta and breast milk
(Calafat et al., 2009; Ikezuki, Tsutsumi, Takai, Kamei, & Taketani,
2002; Sun et al., 2004). However, there are only a handful of human
prospective studies that have assessed birth outcomes following pre-
natal BPA exposure (Snijder et al., 2013). Our recent study found that
elevated first trimester BPA concentrations are associated with
increased oxidative stress (Veiga‐Lopez et al., 2015) leading to low
birth weight in female, but not male offspring (Veiga‐Lopez et al.,
2015). The fact that higher maternal BPA concentrations at term were
not associated with low birth weight (Padmanabhan et al., 2008;
Veiga‐Lopez et al., 2015) in these human studies emphasizes the
importance of windows of susceptibility, particularly during preg-
nancy. Other epidemiological studies have found prenatal BPA expo-
sure to be positively associated with offspring body mass index in
early‐to‐mid‐childhood (Vafeiadi et al., 2016; Yang et al., 2017), which
is also a risk factor for the adult origins of disease.
Animal models have been used to address the effects of BPA on
pregnancy and offspring outcomes to establish causality. Studies withprecocial models, exhibiting developmental trajectories similar to
humans, are essential for establishing causality of developmentally
programmed pathologies that can be translated into novel human
therapies. Sheep models, in particular, have been extensively used to
assess pregnancy outcomes and developmental origin of diseases
stemming from inappropriate exposure to native steroids and environ-
mental steroid mimics (Padmanabhan, Sarma, Savabieasfahani,
Steckler, & Veiga‐Lopez, 2010). Specifically, prenatal exposure to
5 mg/kg/day BPA from gestation day GD30 to GD90 (term:
~147 days), resulting in maternal BPA concentrations twofold higher
than the highest values observed in pregnant US women
(Padmanabhan et al., 2008; Savabieasfahani, Kannan, Astapova, Evans,
& Padmanabhan, 2006), deliver low birth weight female offspring
exhibiting reproductive cycle and metabolic dysfunction, including
insulin resistance, adipocyte hypertrophy, and elevated proinflamma-
tory markers in adipose tissue (Abi Salloum, Steckler, Herkimer, Lee,
& Padmanabhan, 2013; Savabieasfahani et al., 2006; Veiga‐Lopez,
Beckett, Abi Salloum, Ye, & Padmanabhan, 2014).
Considering the non‐monotonic dose‐responses that have been
observed relative to the impact of BPA (Vandenberg et al., 2014), as
well as the limited number of reports addressing the early impact of
BPA in precocial animals, the primary objectives of the present study
were to (1) determine BPA concentrations achieved in both mother
and fetus following gestational exposure to BPA at doses spanning
human exposure levels, and (2) assess the effects of prenatal BPA
exposure on birth and organ weights, and postnatal growth trajectory,
key biomarkers for assessing the risk of adult‐onset disease. As steroid
hormones are major regulators of the growth trajectory, and BPA
alters steroidogenesis (Bloom, Mok‐Lin, & Fujimoto, 2016; Peretz
et al., 2014), our third objective was to determine the effects of prena-
tal BPA exposure on maternal/fetal steroid hormone milieu and its
association with fetal organ weights.2 | MATERIALS AND METHODS
The study was conducted at the University of Michigan Sheep
Research Facility (Ann Arbor, MI; 42° 18′N). All procedures were
approved by the Institutional Animal Care and Use Committee of the
University of Michigan and are consistent with the National Institutes
of Health Guide for Use and Care of Animals. Healthy adult Suffolk
sheep between the ages of 3 and 5 years were purchased from local
farmers and used for generating control and prenatal BPA‐treated ani-
mals. Animals were blocked by maternal weight and body score and
distributed between control and BPA‐treated groups. Details regard-
ing animal maintenance, breeding and lambing have been described
previously (Veiga‐Lopez et al., 2016). Briefly, ewes were group‐fed
daily with 0.5 kg shelled corn and 1.0‐1.5 kg alfalfa hay/ewe and
mated to raddled Suffolk rams. Pregnant ewes maintained good health
throughout the pregnancy. They were weighed weekly and the mean
weight gains during pregnancies were determined. After weaning at
~8 weeks of age, lambs were maintained outdoors and fed a pelleted
1518 VYAS ET AL.diet (Shur‐Gain; Nutreco Canada Inc.) comprised of 3.6 MCal/kg
digestible energy and 18% crude protein.
Two studies were conducted. Study 1 addressed the long‐term
consequences of prenatal BPA treatment and therefore offspring were
maintained from birth to adulthood. Study 2 focused on determining
maternal and fetal milieu and fetal organ weights. For this study, only
the mid dose (0.5 mg/kg/day) was selected, as this was more environ-
mentally relevant.2.1 | Study 1: Effects of prenatal bisphenol A on
birth weight and postnatal growth trajectory
Gestational BPA treatment consisted of daily subcutaneous (s.c.) BPA
injections into dams of 0.05 (low), 0.5 (medium) or 5 (high) mg/kg/day
of BPA (purity ≥99%, cat. no. 239658; Sigma‐Aldrich Chemical Co.) in
corn oil from GD30 to GD90 (term: ~ 147 days). Control dams
received corn oil injections, alone. Umbilical arterial BPA concentra-
tions using the medium dose are already published (Veiga‐Lopez,
Luense, Christenson, & Padmanabhan, 2013) and approximate mater-
nal BPA blood levels have been reported for US women
(Padmanabhan et al., 2008). Offspring were delivered by 14, 21, 26
and 22 dams, respectively, in control, low, medium and high BPA
treatment groups. Final experimental group sizes for control, low,
medium and high BPA treatments were 8, 12, 13 and 7, respectively
for female offspring, and 6, 9, 13 and 15 for male offspring.
Newborn samples were collected by jugular venipuncture in
sodium fluoride/potassium oxalate tubes (BD Vacutainer) and plasma
frozen at −20°C until assayed for glucose and insulin. From day of
birth to 11 weeks of age, females and male offspring were weighed
weekly, after which males were not maintained to avoid unwanted
pregnancies in the flock. After 11 weeks, female weights were taken
weekly until ~6 months of age, and monthly thereafter until they were
~20 months old.2.2 | Study 2: Effect of prenatal bisphenol A on
maternal and fetal steroid, hormones and organ
weights
To determine the early effects of gestational BPA treatment, dams
received daily s.c. injections of either the medium BPA dose
(0.5 mg/kg/day) or corn oil (controls). This medium BPA dose achieved
circulating levels of free BPA of ~2.6 ng/mL in the umbilical artery of
female fetus, approximating median values found in the urine of preg-
nant women and cord blood in human studies (Veiga‐Lopez et al.,
2013). Dams from the control and BPA groups were anesthetized on
GD65 or GD90 with ketamine hydrochloride (Fort Dodge Animal
Health; 3‐4 mg/kg, i.v.) and xylazine (Anased Injection; 0.4 mg/kg/ewe,
i.m.), and subsequently maintained under general anesthesia with
isoflurane (RxElite Holdings Inc.). Umbilical arterial and venous samples
were collected after accessing the gravid uterus via the midline and
uterine wall incisions, as previously described (Veiga‐Lopez et al.,
2011). Samples were frozen until assayed for free and total BPA,androstenedione, cortisol, dehydroepiandrosterone (DHEA),
deoxycorticosterone (DOC), 11‐deoxycortisol, estradiol, estrone,
glucose, insulin, pregnenolone, 17‐hydroxypregnenolone, 17‐
hydroxyprogesterone and testosterone.
Fetuses were then removed and killed by intracardiac barbiturate
administration. Fetal body measures were undertaken and tissues pro-
cured. After removal of fetuses, mothers were also killed with a barbi-
turate overdose (15 mL, i.v. Fatal Plus; Vortech Pharmaceuticals).
Group sizes for GD65 comprised nine female and 11 male fetuses
delivered by 10 dams for BPA, and nine female and six male fetuses
delivered by eight dams for controls. The GD90 groups comprised
nine female and four male fetuses delivered from seven dams for
BPA, and eight female and 10 male fetuses delivered from nine dams
for controls. Fetal measurements included anogenital distance (AGD),
crown to rump length (from the highest midpoint on the top of the
head to the base of the tail), head circumference, fetal weight, as well
as the weights of adrenal, brain, heart, kidney liver, lung, ovaries, tes-
tes, pancreas, pituitary, spleen, thymus, thyroid and uterus. The ratios
of organ weights to body weight were determined.2.3 | Hormonal and metabolic measures
Plasma concentrations of androstenedione, cortisol, DHEA, DOC,
11‐deoxycortisol, estradiol, estrone, pregnenolone, 17‐
hydroxypregnenolone, 17‐hydroxyprogesterone and testosterone
were assayed in a subset of maternal and umbilical cord samples col-
lected at GD65 and GD90. The steroid hormone determinations were
undertaken at the Optimized Analytical Solutions Laboratories, LLC
using high‐performance liquid chromatography (HPLC)/tandem mass
spectrometry (MS/MS) Agilent MassHunter Workstation Data Acqui-
sition for Triple Quad B.03.01 (B2065) and Agilent MassHunter Quan-
titative Analysis for QQQ (B.04.00/Build 4.0.225.0) with electrospray
ionization (ESI). Samples were subjected to a liquid/liquid extraction
method followed by derivatization with dansyl chloride to enable the
detection of estrone and estradiol. Calibration curves of steroid hor-
mone standard/internal standard peak area ratio versus steroid con-
centration were constructed and a weighted 1/×2 linear regression
applied to the data. Concentrations of steroid hormones in samples
were defined based on the appropriate calibration curve. Commer-
cially obtained female monkey plasma was used as quality controls
(for cortisol, estradiol and testosterone: Sigma‐Aldrich; and for andro-
stenedione, DHEA, DOC, 11‐deoxycortisol, estrone, pregnenolone,
17‐hydroxypregnenolone, 17‐hydroxyprogesterone: Steraloids Inc.).
Lower detection limits were: androstenedione 0.1 ng/mL, cortisol
0.5 ng/mL, DHEA 0.5 ng/mL, 11‐deoxycortisol 0.05 ng/mL, DOC
0.05 ng/mL, estradiol 5 pg/mL, estrone 5 pg/mL, pregnenolone
1 ng/mL, 17‐hyrdoxypregnenolone 1 ng/mL, 17‐hydroxyprogesterone
0.2 ng/mL and testosterone 0.02 ng/mL. The respective coefficients
of variation were androstenedione 3%, cortisol 11%, DHEA 8%,
DOC 19%, 11‐deoxcortisol 5%, estradiol 2%, estrone 4%, pregneno-
lone 16%, 17‐hyrdoxypregnenolone 16%, 17‐hydroxyprogesterone
2% and testosterone 8%.
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cord blood samples collected at GD65 and GD90 (study 2) and during
the neonatal period (study 1). Insulin concentrations were measured
using a radioimmunoassay kit (MP Biomedicals). Samples from each
study were each measured within a separate assay and assay sensitiv-
ity averaged 0.61 and 0.39 μU/mL for the two studies. Mean intra‐
assay coefficients of variability (CVs) based on two quality‐control
pools were 3.4% and 7.3%, and 2.7% and 0.4%, respectively.
Interassay CVs were 3.4% and 5.3%, respectively. Glucose concentra-
tions for the two studies (each measured within a separate assay) were
determined using the Glucose Oxidase Method (Pointe Scientific, Inc.)
as described previously. Assay sensitivity was 5.9 and 4.5 mg/dL,
respectively. Intra‐assay CVs were 1.2% and 0.5% (25 mg/dL QC
pool), 1.2% and 0.5% (75 mg/dL QC pool), and 1.6% and 1.3%
(150 mg/dL QC pool), and respective interassay CVs were 4.0%,
0.6% and 0.9%, respectively.2.4 | Bisphenol A measurements
Free BPA (unconjugated) and total BPA were measured using a vali-
dated protocol published from the NIEHS‐funded Round Robin study
in one of the laboratories that participated in the study (Vandenberg
et al., 2014). In brief, after thawing samples at room temperature,
plasma or amniotic fluid (0.5 mL) was transferred to a 15 mL glass
tube, and internal standards (d6‐BPA and 13C12‐BPA‐G), ammonium
acetate buffer, formic acid and Milli‐Q water were added to a total
volume of 3 mL. An Oasis MCX cartridge (60 mg/3 mL; Waters) was
used for the extraction and clean‐up procedure. The cartridge was
preconditioned with methanol and water. After loading the sample,
the cartridge was washed with 15% methanol in water and eluted with
methanol. The eluate was concentrated to 0.5 mL. BPA levels in sam-
ples were quantified using a HPLC coupled with API 5500 ESI triple‐
quadrupole mass spectrometer (ESI‐MS/MS). Ten microliters of the
extract was injected on to an analytical column (Betasil C18,
100 × 2.1 mm column; Thermo Electron Corporation), which was con-
nected to a Javelin guard column (Betasil C18, 20 × 2.1 mm). The
mobile phase comprised methanol and 10 mM ammonium acetate in
water. The ESI‐MS/MS was operated in the electrospray negative
ion mode. Data were acquired using multiple reaction monitoring for
the transitions of 227 > 212 for BPA and 233 > 215 for d6‐BPA.
Quality‐assurance and quality‐control parameters included valida-
tion of the method by spiking internal standards into the sample matri-
ces and passing through the entire analytical procedure to calculate
recoveries of target analytes through the analytical method. A proce-
dural blank was analyzed with the samples to check for interferences
or laboratory contamination. The limit of detection (LOD) was
0.02 ng/mL for BPA. The recovery of d6‐BPA spiked into samples
was 95% ± 29% (mean ± SD). Reported concentrations were corrected
for the recoveries of the surrogate standard (isotope dilution method).
The native standards spiked into procedural blank and selected sample
matrices and passed through the entire analytical procedure yielding
recoveries of 105% ± 5% and 102% ± 7% for BPA, respectively. Anexternal calibration curve was prepared by injecting 10 μL of 0.01‐
100 ng/mL certified BPA standards and the calibration coefficient
was >0.99.2.5 | Validation study
To determine if the sample collection procedure routinely used in the
laboratory leaches BPA, three females were administered a single BPA
dose (0.5 mg/kg birth weight; s.c.). Two simultaneous plasma samples
were collected before, and 6 and 24 hours after BPA administration
using both a routine collection procedure (involving plastic instru-
ments) and a plastic‐free collection procedure. For the routine proce-
dure, plastic syringes (BD) for blood extraction and plastic Pasteur
pipettes (Fisher) for plasma transfer to storage plastic tube (DOT)
sealed with a plastic cap (DOT) were used. For the plastic‐free proce-
dure, a vacutainer blood extraction system (BD) was used and blood
was collected in a vacutainer glass tube (BD). Plasma was then trans-
ferred to a glass tube (Fisher) with a glass Pasteur pipette (Fisher).
All samples were immediately frozen and stored at −20°C.2.6 | Statistical analysis
Postnatal growth data were collected for 11 weeks in male offspring
and 86 weeks (~600 days) in female offspring. In the first analysis,
birth weight and growth curves from birth to 11 weeks of age using
all offspring (including both female and male animals) among treat-
ment groups were analyzed. A linear random effect mixed model
was used for both analyses to account for correlation between lambs
born to the same mother and repeated measurements from the same
offspring. Quadratic function was found to fit the growth curve well
from birth to 11 weeks of age. A second analysis was then conducted
to study long‐term postnatal weight trajectories in female offspring,
alone. Quadratic splines with knots at 3 and 6 months of age were
used to fit the growth curve. For all the above analyses, all BPA dose
groups were combined before comparing them to the controls.
For all analyses: to assess and adjust for sex differences, sex and
treatment interaction was tested in each model; to adjust for litter
size, numbers of female and male siblings in the same litter were
included in the model. In addition, comparisons of fetal organ weights,
fetal steroids and fetal hormonal measures were made using a regres-
sion model. Interactions between data collection time and gender
(data collection and treatment) were assessed, within BPA‐treated
and control (male and female) groups, respectively.
Appropriate transformations were applied, as needed, to account
for normality of data. Comparisons of fetal BPA concentrations (free
and total) were analyzed using a mixed model with Tukey post‐hoc
tests with the number of fetuses as a covariate.
For the analysis of maternal steroidal measures and insulin‐to‐
glucose (I/G) ratio in study 2, two‐tailed t‐test was performed.
Comparisions for fetal I/G ratio were made between BPA vs. controls
in each sex using the Mann‐Whitney test. In addition, same sex fetuses
born to the same dam were averaged within each group to account for
TABLE 1 Mean birth weight for each treatment group by sex and
I/G ratio for each treatment group by sex in newborn lambs
Female Male
Treatment group
Mean ± SD Mean ± SD
n n
A, Mean birth weight for each treatment group by sex
BW (kg) Control 6.22 ± 1.44 6.60 ± 0.94
1520 VYAS ET AL.dam effects. A univariate analysis of variance was used for comparing
the newborn I/G ratio (study 1) and maternal weight gain.
Spearman's correlation analysis was performed to relate significant
outcomes in study 2 with maternal/fetal BPA (free and total) levels. All
statistics were run using PASW Statistics for Windows release 18.0.1
or SAS (Windows version 9.4) and all plots were generated using R
software. Differences were considered significant at P < .05. All data
are presented as mean ± SEM unless otherwise stated.
8 6
Low 5.88 ± 1.02 6.22 ± 1.44
12 9
Medium 5.42 ± 1.07 6.36 ± 1.66
13 13
High 5.90 ± 1.42 5.66 ± 1.27
7 153 | RESULTS
The mean weight gains during pregnancy were 1.20, 1.36, 1.54 and
1.96 kg for the control, BPAlow, BPAmedium and BPAhigh respectively
and did not differ significantly between control and BPA‐treated
groups (P = 1.00 for all three comparisons).
B, I/G ratio for each treatment group by sex in newborn lambs
I/G ratio Control 0.20 ± 0.06 0.16 ± 0.04
5 5
Low 0.13 ± 0.04 0.18 ± 0.10
7 6
Medium 0.15 ± 0.04 0.20 ± 0.09
10 7
High 0.16 ± 0.11 0.16 ± 0.07
5 9
BPA, bisphenol A; BW, birth weight; I/G, insulin‐to‐glucose ratio; n, num-
ber of lambs per group; SD, standard deviation.
BPA doses: 0.05, 0.5 or 5 mg/kg/day (referred to as: low, medium and
high, respectively).3.1 | Study 1: Effects of prenatal bisphenol A on
birth weight and early postnatal growth trajectory
(0‐11 weeks)
Table 1A shows the mean birth weight for each treatment group by
sex. As expected, the birth weights of female offspring were
significantly lower compared with males (P = .0023). There was no
treatment effect on birth weight for either sex when the three BPA‐
treated groups were analyzed separately or combined. Growth trajec-
tories from birth to 11 weeks of age are shown in Figure 1. Growth
curves differed significantly between treatment groups and sex
(P < .0001), as described below. Despite the similarity in birth weight,
the growth rate of BPA‐treated males after birth (Figure 1, left panels)
differed from controls. While control males grew ~2.7 kg/week during
week 1, prenatal BPA‐treated males grew more slowly (~2.0 kg/week;
P = .0004). In control males, growth rates remained approximately the
same during the subsequent 11 weeks. In contrast, the growth rate of
BPA males increased over time (P < .0001). By ~6 weeks of age, the
BPA male growth rate approximated that of control males. By
10 weeks of age, BPA males grew faster than control males (P = .0052;
Figure 1, left panels). Immediately after birth, control females grew
~1.7 kg/week, while BPA females grew faster (~2.1 kg/week; P = .030;
Figure 1, right panels). The growth rate increased with increasing age
in both the control and BPA groups, but was less pronounced in
BPA‐treated females (P < .001). By 10 weeks of age, growth rates in
control and BPA females were similar.
Table 1B shows the I/G ratio in newborn lambs. There was no dif-
ference in the I/G ratio between the BPA and control females (P = .22,
.41 and .61 respectively, for BPAlow, BPAmedium and BPAhigh) or males
(P = .91, .63 and .99 respectively).3.2 | Effects of prenatal bisphenol A on later growth
trajectory (up to 86 weeks of age) in female offspring
The weights of control and prenatal BPA‐treated females from birth to
86 weeks of age are shown in Figure 2. As opposed to the increasedgrowth rate of BPA‐treated females during the first few weeks, con-
trol females showed a higher growth rate compared with the BPA‐
treated group at 13 weeks of age. Growth rate was 2.98 kg/week in
control vs. 2.76 kg/week in BPA‐treated females (P = .0029) at
13 weeks of age. At 26 weeks, growth rates had slowed in both
groups (controls 0.77 vs. BPA 0.61 kg/week; P = .0074). By 80 weeks,
growth rates for both groups were minimal and did not differ (controls
0.00 vs. BPA 0.1 kg/week; P = .28).3.3 | Study 2: Effect of prenatal bisphenol A on
maternal fetal bisphenol A measures
The mean unconjugated and total BPA concentrations in sheep cord
blood, amniotic fluid and maternal circulation is shown in Figure 3.
The majority of BPA in maternal and cord blood, as well as amniotic
fluid was in the conjugated form (Figure 3A vs. 3B) at both gestational
time points. Concentrations of free and total BPA were significantly
higher in BPA‐treated groups compared with control groups in both
maternal and fetal circulation (white asterisks). In general, free BPA
concentrations were 10‐fold lower in fetal circulation compared with
maternal circulation at GD65 in both male and female fetuses
FIGURE 1 Growth trajectory and growth rate from birth to 11 weeks in males (left panels) and females (right panels) from control and
BPA‐treated groups. Top panels: means and standard errors of observed weight over time by treatment groups. Middle panels: estimated
growth trajectories of the control and pooled BPA‐treated groups based on the linear mixed effects model. Bottom panels: estimated weekly
growth rate of the control and pooled BPA‐treated groups, based on the linear mixed effect model. *P < .05 for comparing growth rate between
control and pooled BPA‐treated groups. BPA, bisphenol A
VYAS ET AL. 1521
[Colour figure can be viewed at wileyonlinelibrary.com](Figure 3A; a vs. b), but were comparable at GD90. Total BPA concen-
trations achieved were similar in maternal and fetal circulation at
GD65 (Figure 3B). In contrast, total BPA concentrations achieved
were twofold higher in both male and female fetal circulation and
amniotic fluid compared with maternal circulation on GD90. TotalBPA concentrations in both male and female fetuses at GD90 were
elevated compared with concentrations on GD65.
Focusing on sex differences, there were no differences in free BPA
concentrations between male and female fetuses on GD65 or GD90 in
the BPA‐treated group, although in controls, higher concentrations of
FIGURE 2 Weights from birth to 86 weeks for females in the control
(solid black line) vs. all BPA groups combined (dashed line). *At birth,
growth rate was 2.1 kg/week for BPA and 1.6 kg/week for controls,
P < .0001; at 13 weeks, growth rate was 2.76 kg/week for BPA and
2.98 kg/week for controls, P = .0029; at 26 weeks, growth rate was
0.61 kg/week for BPA and 0.77 kg/week for controls, P = .0074. BPA,
bisphenol A
1522 VYAS ET AL.BPA were evident in males compared with females on GD65 (Figure 3
A, gray diamond). In contrast, higher concentrations of total BPA were
observed in BPA‐treated males compared with females at GD65, but
not GD90.
Validation studies in sheep provided no evidence of BPA contam-
ination originating from any of the collection system used (Figure 4).3.4 | Effects of prenatal bisphenol A on hormones
and metabolic measures
No difference was observed between BPA vs. control group in mater-
nal I/G ratio at GD65 (BPA 0.20 ± 0.04 vs. controls 0.18 ± 0.05 units)
or at GD90 (BPA 0.20 ± 0.05 vs. controls 0.16 ± 0.06). Similarly, there
was no difference between BPA vs. control groups in the fetal I/G
ratio at GD65 (females 1.48 ± 0.33 vs. 9.10 ± 14.69; males
1.57 ± 0.72 vs.5.61 ± 3.94, respectively). At GD90, BPA‐treated
females tended to have a lower I/G ratio compared with controls
(BPA 1.86 ± 0.97 vs. controls 4.76 ± 2.44, P = .052). No such differ-
ence was evident in males (BPA 1.8 ± 0.54 vs. controls 2.1 ± 1.29).
Maternal steroidal measures are summarized in Table S1 (see
Supporting Information). Measures of DHEA, androstenedione, 17‐
hydroxypregnenolone, 17‐hydroxyprogesterone and testosterone
were under the LOD for the assay used in both maternal and fetal
samples. BPA treatment increased maternal corticosterone concentra-
tions at day 65 (P = .036) and pregnenolone level at GD90 (P = .004).
DOC in the maternal circulation tended to be higher at day 65 with
BPA treatment. Fetal steroidal profiles are summarized in Table S2
(see Supporting Information). There was no significant interaction
between sex and treatment at GD65 or GD90 (Table S2a; see
Supporting Information). When comparing within treatment groups,
progesterone and pregnenolone concentrations in females were sig-
nificantly higher in the BPA compared with control females at GD65.Interestingly, when comparing ratios of adrenal steroid precursors
we noted increased ratios of progesterone to DOC in the BPA‐treated
females compared with control females at GD65 (Table S2b; see
Supporting Information). Corticosterone and DOC were significantly
lower in BPA females compared with control females at GD90, but
similar differences were not seen between BPA and control male
fetuses and there were no differences in adrenal steroid precursor
ratios (Table S2b; see Supporting Information). Deoxycortisol and cor-
tisol were also significantly lower in control females compared with
control males at GD90. At GD90, BPA‐treated males had significantly
higher deoxycortisol than BPA females (Table S2b; see Supporting
Information). Except from pregnenolone, which correlated with total
BPA at day 65 in the female fetus (R = 0.683 P = .029), none of the
other adrenal steroids that were significantly altered correlated with
either free BPA or BPA.3.5 | Effects of prenatal bisphenol A on fetal weight,
size and organ weights
Fetal body weight and anthropometric measurements are shown in
Table 2. In the control group, no differences were observed in fetal
body weight, head circumference or crown to rump length between
females and males at GD65 or GD90. In BPA fetuses, males had larger
body weights than females at GD90 (P = .008), but not at GD65
(Table 2). As expected, AGD was greater in males compared with
females in both the control and BPA groups at both GD65 and GD90
(Table 2). The within‐sex comparison of the control and BPA groups
found that BPA males tended to have higher body weights compared
with control males (P = .061).
Organ/body weight ratios for heart, liver, thyroid and gonads are
shown in Table 3 (other organ weights are summarized in Table S3;
see Supporting Information). No significant differences were noted
between sex when compared within each treatment group (Table 3);
however, the heart/body weight ratio tended to be lower in control
males compared with control females at GD65 (P = .091), the BPA
males tended to have an increased heart/body weight ratio at GD90
(P = .061) compared with BPA females.
Focusing on the BPA treatment effect within each sex, BPA
females had a lower liver/body weight ratio relative to the control
group (P = .023) at GD90 (Table 3). Similar differences were not
observed in BPA males at both gestational ages. In contrast, BPA
males had a higher heart/body weight ratio compared with controls
(P = .030) at GD90 (Table 3). No differences in gonadal (ovary or tes-
tis)/body weight ratios were evident between the control and BPA
groups at both gestational time points.
A significant increase in the thyroid/body weight ratio was evident
in BPA males compared with controls at GD65 (P = .028) (Table 3).
There were no other differences in the organ/body weight ratio with
lungs, pancreas, kidney, adrenal and pituitary (Table S3; see
Supporting Information). Spearman correlation analysis revealed no
significant correlation between the organ weight/body weight ratio
for heart, liver and with either free or total BPA.
FIGURE 3 A, Free BPA. B, Total BPA. Mean (±SEM) concentrations of free and total BPA in maternal blood (left) and umbilical artery blood and
amniotic fluid (right) and samples at gestational day 65 (top) and 90 (bottom) in C (open bars) and BPA‐treated (closed bars) groups. White
Asterisks denote significant difference between C and BPA for each category. Diamond symbol (C: gray; black: BPA group) symbol indicate male
vs. female differences in BPA levels at each time point. a vs. b indicate differences between maternal vs. fetal levels of BPA achieved (C: gray;
black: BPA group). X vs. Y (C: gray; black: BPA group) indicate differences in BPA levels achieved between days 65 and 90 within each category for
each sex. BPA, bisphenol A; C, control; GD, gestational day
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To our knowledge, this study is the first to assess the sex‐specific
effects of gestational BPA exposure on fetal anthropometrics and
postnatal growth trajectory in a precocial mammalian model, which
reveals significant sex‐by‐treatment interactions. Gestational BPA ledto the sexually dimorphic effects on fetal organ weights, with liver
weight affected in females in contrast to heart and thyroid weights
in males. Sex differences were also evident in early postnatal growth
trajectories with BPA males growing more slowly than controls during
the early postnatal period followed by catch‐up growth, while BPA
females showed increased growth early on followed by the slowing
FIGURE 4 BPA validation study. Three sheep females were administered a single BPA dose (0.5 mg/kg birth weight, s.c.) was administered to
each female. Two simultaneous plasma samples were collected before, 6 and 24 h after the BPA dose using both a routine collection
procedure (involving use of plastic instruments) and a plastic‐free collection procedure. BPA, bisphenol A
TABLE 2 Anthropometric measurements of fetuses: Comparing BPA (0.5 mg/kg dose) vs. control within each sex and comparing male vs. female
within each treatment group at GD65 and GD90
Female Male
GD
Control BPA Control BPA
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
n n n n
FW (g) 65 126.67 ± 18.7 124.44 ± 21.3 143.33 ± 36.7 140 ± 17.9
9 9 6 11
90 662.5 ± 97.1 647.78 ± 32.3a* 653 ± 45.5 715 ± 59.2b*
8 9 10 4
HC (cm) 65 13.31 ± 1.1 13.3 ± 0.8 13.17 ± 0.6 13.76 ± 1.1
9 9 6 11
90 21.34 ± 0.8 21.27 ± 0.9 21.15 ± 0.7 21.58 ± 0.6
8 9 10 4
CR (cm) 65 16.18 ± 1.6 16.14 ± 1.5 15.82 ± 1.4 16.38 ± 1.5
9 9 6 11
90 27.91 ± 1.3 27.64 ± 0.9 27.17 ± 1.4 26.93 ± 3.9
8 9 10 4
AGD (cm) 65 0.32 ± 0.1a* 0.28 ± 0.1a* 2.57 ± 0.16b* 2.39 ± 0.3b*
9 9 6 11
90 0.71 ± 0.2a* 0.96 ± 1.1a* 4.16 ± 0.4b* 4.20 ± 0.4b*
8 9 10 4
AGD, anogenital distance; BPA, bisphenol A; CR, crown to rump; FW, fetal weight; GD, gestational day; HC, head circumference; n, number of lambs per
group; SD, standard deviation.a ≠ b denotes differences between sex within treatment groups P < .05. A ≠ B denotes differences between treatment
groups within sex, P < .05.
*P value adjusted for no. of fetuses per ewe. FW day 90 BPA female vs. BPA male P = .008, AGD for control male vs. female at GD65 and GD90, P ≤ .001.
AGD for BPA male vs. female at GD65 and GD90, P ≤ .001.
1524 VYAS ET AL.of growth. Although the contribution of sexually dimorphic differences
in fetal concentrations of total BPA achieved on GD65 following
gestational BPA exposure remains unclear, the relevance of the sex‐
specific impact of BPA on fetal organ weights, steroidal profiles and
growth trajectories are discussed below.
4.1 | Maternal and fetal concentrations of
bisphenol A
Consistent with the transplacental transfer of BPA seen in earlier stud-
ies (Balakrishnan, Henare, Thorstensen, Ponnampalam, & Mitchell,2010; Gingrich et al., 2019; Ikezuki et al., 2002; Schonfelder et al.,
2002), we observed transplacental transfer of BPA to the fetus with
measurable concentrations of free BPA detectable in umbilical cord
blood. In this assessment of chronic BPA exposure at two time points
during pregnancy (GD65 and GD90 of a 147‐day gestation preg-
nancy), concentrations of free and total BPA in maternal circulation
were comparable between GD65 and GD90, indicative of the short
half‐life and fast clearance of BPA reported in earlier studies (Collet
et al., 2010; Gingrich et al., 2019; Viguie et al., 2013) and supportive
of a lack of an accummulation of BPA in the maternal compartment
after chronic BPA exposure. Maternal and umbilical cord
TABLE 3 Fetal organ weights: Comparing BPA (0.5 mg/kg dose) vs. control within each sex and comparing male vs. female within each treat-
ment group at GD65 and GD90
Female Male
Ratios GD
Control BPA Control BPA
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
n n n n
Heart/body weighta 65 0.909 ± 0.228 0.826 ± 0.129 0.750 ± 0.063 0.782 ± 0.085
9 9 6 11
90 0.836 ± 0.089 0.824 ± 0.073 0.852 ± 0.075B* 0.983 ± 0.126A*
8 9 10 4
Liver/body weighta 65 6.822 ± 0.828 6.501 ± 0.568 6.407 ± 0.785 6.220 ± 0.576
9 9 6 11
90 5.129 ± 0.495B* 4.895 ± 0.329A* 4.993 ± 0.639 5.307 ± 0.783
8 9 10 4
Thyroid/body weighta 65 0.051 ± 0.024 0.040 ± 0.013 0.045 ± 0.010 0.035 ± 0.012
9 9 6 11
90 0.038 ± 0.015 0.041 ± 0.009 0.040 ± 0.008B* 0.052 ± 0.011A*
8 9 10 4
Gonadb/body weighta 65 0.021 ± 0.008 0.025 ± 0.008 0.051 ± 0.021 0.048 ± 0.008
9 9 6 11
90 0.006 ± 0.001 0.007 ± 0.002 0.043 ± 0.019 0.064 ± 0.035
8 9 10 4
BPA, bisphenol A; GD, gestational day; SD, standard deviation.
aAdjusted for body weight, then multiplied by 100. A ≠ B denotes differences between treatment groups within sex, P < .05.
bOvaries in females and testes in males.
*P value adjusted for no. of fetuses per ewe. Female liver BPA vs. control P = .023, male heart BPA vs. control P = .03, thyroid, P = .028
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administration of an environmentally relevant dose of BPA have not
previously been studied in detail. One study investigating the pharma-
cokinetics of BPA in fetal plasma following single maternal intravenous
infusion of 1 mg/kg of BPA in sheep found concentrations
approaching ~90 ng/mL 1 hour postinjection (Gauderat et al., 2017).
Maternal concentrations of free BPA achieved in the present study,
averaging 12.2 and 26.5 ng/mL respectively at GD65 and GD90, are
within the the range reported in a Korean study (range 0.44‐
47.1 ng/mL) (Lee et al., 2018) and our Michigan‐based study during
the first trimester (<LOD to 96.43 ng/mL) and at term (<LOD to
89.60 ng/mL) (Veiga‐Lopez, Kannan, et al., 2015). Umbilical cord blood
concentrations of ~2 ng/mL of free BPA, achieved in the present
study at both GD65 and GD90 following daily s.c. administration of
0.5 mg/kg/day BPA, are also within the range of free BPA found in
mid‐gestation umbilical cord blood concentrations (<LOD
52.26 ng/mL) in a California‐based study (Gerona et al., 2013), at term
cord blood concentrations (<LOD 51.5 ng/mL) in the Korean study
(Lee et al., 2018) and in our Michigan‐based study (<LOD 41.83 ng/mL)
(Veiga‐Lopez, Kannan, et al., 2015).
Comparative estimates of free and total BPA in the cord blood of
humans are limited. The umbilical cord concentrations of BPA glucuro-
nide in theCalifornia study (<LOD3.05 ng/mL) and our humanMichigan
study (<LOD 4.85 ng/mL) (Gerona et al., 2013; Veiga‐Lopez, Kannan,
et al., 2015) are much lower than the free BPA concentrations. In con-
trast, total BPA concentrations are higher than free BPA in our sheepstudy. In addition, in the present study, the ratio of free‐to‐total BPA
is much lower in umbilical and aminiotic fluid compared with that seen
in maternal circulation. The high presence of total BPA over free BPA
in the sheep study indicates that the fetal‐placental unit is efficient in
metabolizing BPA into its conjugated form, and that conjugated metab-
olites appear to accumulate in the fetal placental compartment. High
concentrations of accumulated conjugated BPA in the sheep fetus have
been reported following a single intravenous infusion of BPA (Corbel
et al., 2013). As BPA has been shown to be de‐conjugated in the liver,
these findings suggest that enzymes required for de‐conjugation and
elimination of BPA may not be fully functional in the fetal liver
(Coughtrie, Burchell, Leakey, & Hume, 1988). The sex differences in
levels of BPA achieved at GD90 may reflect differences in
metabolism/clearance of BPA between males and females. Accumula-
tion of conjugated BPA in the fetal compartment may have physiologi-
cal relevance, as BPA glucuronide has also been reported to be
biologically active (Boucher, Boudreau, Ahmed, & Atlas, 2015). Finally,
the validation study we have conducted negates the concern that some
of the measured BPA reflects processing contamination.4.2 | Prenatal bisphenol A programming of
organogenesis and fetal growth
There are limited epidemiological studies addressing the association of
prenatal BPA exposure on organogenesis and/or fetal health. Most
1526 VYAS ET AL .human studies have focused on birth outcomes as the endpoint of
prenatal exposure to BPA. A recent study noted that elevated mater-
nal concentrations of BPA in mid‐late gestation were correlated with
impaired fetal growth and head circumference (Snijder et al., 2013).
Interestingly, sex differences in birth outcomes of maternal BPA expo-
sure have been reported in a recent study, with elevated risk for large‐
for‐gestational age, as well as small‐for‐gestational age male neonates
depending on exposure dose of BPA. Similar effects on birth weight
were not evident in female offspring (Chou et al., 2011). Interestingly,
BPA‐treated male fetuses were found to be also heavier than BPA‐
treated females at GD90 in the present study, possibly reflecting the
increased concentrations of total BPA found in GD65 males.
Lack of effect of prenatal BPA treatment on birth weight at all
doses in study 1 differs from that of our previous study where we
found that prenatal BPA (5 mg/kg/day) resulted in decreased body
weight of female fetuses (Savabieasfahani et al., 2006). These differ-
ences may reflect changes in environmental conditions. Epidemiologi-
cal studies investigating the association of BPA with birth weight are
also inconsistent, with some studies reporting a reduction (Burstyn
et al., 2013; Miao, Yuan, Zhu, He, & Li, 2011; Snijder et al., 2013) or
no change (Padmanabhan et al., 2008), while others report an increase
(Lee et al., 2008) or U‐shaped response curve (Philippat et al., 2012).
These discrepancies in birth weight variability could be explained by
both the exposure and timing of BPA exposure during pregnancy
and interaction with other environmental exposures, diet and/or life-
style factors.
In contrast to the lack of effects on birth weight, significant sex‐
and time‐specific effects of prenatal BPA treatment, although not
directly correlated, were evident in the organs involved in cardiomet-
abolic function. In females, this is manifested by decreased fetal liver
weight at GD90. The lower levels of total BPA in female GD65 fetuses
compared with males in the face of reduced liver weight suggest
female fetuses may metabolize BPA quicker than males. Available evi-
dence indicates BPA accumulates in human fetal liver and elevated
BPA is associated with adult liver dysfunction (Lee et al., 2014; Nahar,
Kim, Sartor, & Dolinoy, 2014; Nahar, Liao, Kannan, Harris, & Dolinoy,
2015). While studies addressing causal relationships between prenatal
exposure to BPA on postnatal programming of human liver are not
feasible, animal studies show that developmental exposure to BPA
induces alterations in hepatic gene expression and diseases such as
hepatic steatosis, liver tumors and metabolic syndrome (DeBenedictis,
Guan, & Yang, 2016; Moustafa & Ahmed, 2016; Wei et al., 2014); e.g.,
prenatal BPA from embryonic day 7.5 to 18.5 in mice affects liver mat-
uration in a sex‐specific fashion with effects seen only in females
(DeBenedictis et al., 2016). Another study also found exposure to
BPA 25 μg/kg/day from GD8 through postnatal day 16, increased
hepatic lipid content in 5‐ and 39‐week‐old females, but not male mice
(Shimpi et al., 2017). Other animal studies exploring the impact of BPA
on liver focused on either of the sexes; e.g., a study focusing on male
offspring noted that, at exposure to 50 mg/kg/day BPA from GD0 to
the end of lactation at postnatal day 21, results showed abnormalities
of liver function and hepatic damage in male rats (Xia et al., 2014).
Similarly, prenatal BPA treatment was found to program fatty liverdisease in male offspring when subjected postnatally to a high‐fat diet
(Wei et al., 2014). In contrast, a study in mice focusing on female off-
spring showed that exposure to 50 and 200 mg/kg birth weight BPA
from the beginning of gestation through 3 months postweaning
increased vacuolation of hepatic cells, proliferation of Kupffer cells
and altered liver enzymes in females (Moustafa & Ahmed, 2016).
The decrease in fetal female liver weight seen in our study reflecting
early programming effects may contribute to later metabolic
dysfunctions.
As opposed to lack of effect of prenatal BPA on fetal male liver,
prenatal BPA treatment increased the heart/body weight ratio at
GD90 in males, alone. Consistent with the lack of effect on the female
heart during fetal life, there were no effects of prenatal BPA treatment
on blood pressure or morphometric measures in adult BPA‐treated
offspring (Koneva et al., 2017; MohanKumar et al., 2017). However,
prenatal BPA treatment upregulated several genes involved in the reg-
ulation of myocardium growth, heart development and remodeling,
and the downregulation of genes involved in cellular respiration and
inflammation in adult prenatal BPA‐treated females (Koneva et al.,
2017). Prenatal BPA treatment was also found to reduce collagen
expression in the right ventricle (MohanKumar et al., 2017). These
changes have the potential to lead to cardiac compromise with adult
aging. The changes in fetal heart weight, while not correlating with
measured BPA levels, may serve as proxy for later functional defects
that may develop in the male. Cardiac‐specific studies have not been
carried out in adult, prenatal BPA‐treated rams. In our studies, males
were not maintained in parallel with females.
The male‐specific effect of prenatal BPA on the thyroid, an impor-
tant regulator of metabolic functions, including hepatic steatosis
(Mullur, Liu, & Brent, 2014), is of interest. Our findings of increased
thyroid weight in prenatally treated BPA male fetuses, coupled with
recent findings in sheep that prenatal BPA treatment induces disrup-
tion of fetal thyroid function (Guignard et al., 2017), raises the possi-
bility that prenatal exposure to BPA may compromise thyroid
function in adulthood. This does not hold true with females, as thyroid
gland size was not affected (this study). EDCs have been shown to
affect thyroid function (Miller, Crofton, Rice, & Zoeller, 2009). BPA
in particular has been shown to affect thyroid volume (BPA concentra-
tions inversely associated with thyroid volume) and affect thyroid
function in human studies (Meeker & Ferguson, 2011; Wang et al.,
2015; Zoeller, 2007). Prenatal exposure to BPA at around the third tri-
mester of pregnancy has been shown to affect the offspring thyroid
axis in a sex‐specific pattern, with conflicting data in one study show-
ing elevated BPA correlated with low thyroid‐stimulating hormone in
male neonates and others showing the same pattern in female neo-
nates (Chevrier et al., 2013; Romano et al., 2015). Similarly in rodent
studies, there are conflicting data on the sex‐specific effects of BPA
on the thyroid gland with effects seen in both sexes vs. male alone
vs. no effect on either sex (Kobayashi et al., 2005; Xu et al., 2007;
Zoeller, Bansal, & Parris, 2005). Prenatal BPA exposure is shown to
alter thyroid hormone in sheep; however, this effect was not sex spe-
cific and there was no mention on fetal thyroid organ weight (Viguie
et al., 2013). As the thyroid has been shown to have a critical role in
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2011; Smallridge & Ladenson, 2001), further studies to assess the
functional effects of this sex‐specific pattern of change in size of thy-
roid gland are warranted.
Interestingly, while we saw sex‐specific effects of BPA on fetal
organ weights we did not see sex differences in fetal organ weights.
To what extent these sex‐specific effects of BPA have on organ sys-
tems are key to cardiometabolic function are the result of masculiniza-
tion or defeminization of systems is an important line of research. Our
studies found no effect of BPA on AGD, a biomarker for masculiniza-
tion at GD65 and GD90 in both sexes, although the expected increase
in AGD was evident in the males at GD65 and GD90 compared with
females in both control and BPA‐treated groups. In contrast, an earlier
study found prenatal BPA exposure reduced AGD in male offspring
(Mammadov, Uncu, & Dalkan, 2018; Miao et al., 2011).4.3 | Prenatal bisphenol A and maternal/fetal
steroidogenesis and metabolic measures
Because steroid hormones can program fetal growth and adult pheno-
type, and BPA has been shown to influence steroidogenesis (Peretz
et al., 2014), we investigated the impact of prenatal BPA treatment
on maternal and fetal steroidogenesis. Lack of effect of prenatal BPA
treatment on maternal and fetal estrogens may suggest the program-
ming of adult reproductive and metabolic dysfunction by prenatal
BPA treatment (Alonso‐Magdalena, Quesada, & Nadal, 2015) are not
mediated via changes in maternal and fetal estrogens. However, we
did note a significant increase in corticosterone in the BPA‐treated
mothers at GD65, but not at GD90. In general, maternal stress raises
corticosterone concentrations during pregnancy with negative effects
on a feto‐placental unit (Jafari, Mehla, Afrashteh, Kolb, & Mohajerani,
2017; Vaughan, Sferruzzi‐Perri, & Fowden, 2012). Elevations in corti-
costerone rather than cortisol concentrations strongly correlate with
fetal stress in human studies (Wynne‐Edwards, Edwards, & Hancock,
2013). Despite elevated corticosterone in maternal circulation, corti-
costerone and DOC, which are both downstream products in the
adrenal steroidal pathway leading to aldosterone synthesis, were
lower in the D90 BPA‐exposed female fetuses. While similar changes
in corticosterone and DOC levels were not seen in the GD65 BPA‐
exposed female fetuses, higher levels of pregnenolone and progester-
one, upstream products of the aldosterone synthetic pathway and a
higher progesterone/DOC ratio were evident. These findings could
be suggestive of a fetal compensatory response to overcome inhibi-
tion of adrenal enzyme activity upstream (e.g., CYP21) of the aldoste-
rone synthesis pathway. Owing to multiple precursors being below the
level of detection, similar assessment of cortisol and androgen path-
ways were not possible. A recent in vitro study with a human cell line
found BPA altered adrenal steroidogenesis by inhibiting CYP17 (Zhang
et al., 2011) and, similar to our study, noted an increase in progester-
one and a decrease in downstream steroidal hormone levels. One
possibility is prenatal BPA‐blocked CYP17 activity leading to unmea-
surable downstream steroidal products.In epidemiological studies, BPA exposure has been shown to be
associated with type 2 diabetes (Lang et al., 2008). In rodent models,
prenatal BPA has been shown to lead to insulin resistance in the male
offspring (Alonso‐Magdalena et al., 2015). Our group has previously
shown that female offspring exposed to prenatal BPA also develop
reduced insulin sensitivity in adulthood (Veiga‐Lopez et al., 2016). To
our knowledge, this is the first study to assess insulin sensitivity in
fetal circulation at early and later gestation in both sexes. A trend
for increased insulin sensitivity only in the BPA‐treated female fetus
at GD90 in the absence of such differences in the maternal or new-
born circulation may be a reflection of early programming effects of
BPA on insulin homeostasis (Veiga‐Lopez et al.,2016). Lack of effect
of BPA on maternal insulin sensitivity suggests that the effects of
BPA on the insulin sensitivity of adult offspring are programmed indi-
rectly via other maternal mechanisms or through direct effects at the
fetal level.4.4 | Prenatal bisphenol A programming of
sexually‐dimorphic postnatal growth trajectory
A significant sex difference was evident in early postatal growth tra-
jectory of prenatal BPA‐treated offspring, independent of the BPA
dose. Prenatal BPA‐treated female lambs grew faster immediately
after birth with slowing of growth velocity over time compared with
their control counterparts. In contrast, prenatal BPA‐treated males
grew slower in the immediate postnatal period, but had an increased
growth rate over time compared with the control group. Such sex dif-
ferences in growth trajectories may be related to higher concentra-
tions of total BPA found in male fetuses during early gestation
(GD65). While the relative biological potency of conjugated BPA is
unknown, there is some evidence for bioactivity of the glucuronide
form of BPA (Boucher et al., 2015). Native steroids such as estrogen,
when conjugated with bovine serum albumin have the capability to
stimulate surface receptors leading to rapid signaling (Chen et al.,
2017; Watson, Hu, & Paulucci‐Holthauzen, 2014). Considering the
estrogenic properties of BPA, it is conceivable the same holds true
for the conjugated form of BPA.
Low birth weight followed by rapid catch‐up weight gain have been
shown to lead to adverse cardiometabolic phenotype in adulthood
(Barker, 2004). Although we did not see low birth weight in our cohort,
the female offspring did show a brief period of increased weight gain
soon after delivery. One epidemiological study reported larger
increases in body mass index slope from 2 to 5 years associated with
higher BPA with association being stronger in girls, while another
found girls exposed to higher concentrations of prenatal BPA have
lower body mass index in childhood (Braun et al., 2014; Harley et al.,
2013). The increased growth rate evidenced in our study may
contribute to the insulin resistance and increase in adipocyte size and
inflammatory markers evidenced in adult prenatal BPA‐treated sheep
(Veiga‐Lopez et al., 2016). The implication of the initial slower trajec-
tory of postnatal weight gain followed by increased weight gain veloc-
ity later in males needs to be explored further, as several other factors
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mental chemicals and their interaction with diet could also be playing a
role. Considering that low birth weight followed by catch‐up growth
has been shown to lead to cardiometabolic diseases later in life (Barker,
2004; Valsamakis et al., 2006), the enhanced growth rate in the
absence of change in birth weight is also a potential risk factor.
Finally, the major strengths of our current study assessing the
impact of prenatal BPA on fetal and postnatal health of the offspring
are: (1) use of sheep as the precocial species, which have a similar
developmental trajectory as humans; (2) use of three different doses
of BPA spanning environmental to occupational exposure concentra-
tions; (3) measurement of both free and total BPA concentrations
using a well validated assay (Vandenberg et al., 2014; Veiga‐Lopez,
Kannan, et al., 2015) at two different time points in fetal and maternal
serum allowing exploration of the contribution of a time‐specific
impact of BPA; (4) use of LCMS for measures of steroid hormones
allowing for improved accuracy of steroid measures; and (5) more
importantly, to the best of our knowledge, the first longitudinal study
of assessment of the sex‐specific impact of prenatal BPA on growth
trajectory. Study limitations include lack of follow‐up of the male off-
spring beyond 11 weeks of age in parallel with the female offspring, a
necessity to avoid unwanted pregnancy in our cohort, and absence of
information on adult male phenotype to relate these early findings.
In conclusion, this study documents internal concentrations of
maternal and fetal BPA achieved at two time points in gestation fol-
lowing the treatment of pregnant sheep with environmentally relevant
doses of BPA. Importantly, the study demonstrates sexually dimorphic
effects of prenatal BPA on organogenesis and early postnatal growth
trajectory—aspects of relevance to the programming of adult repro-
ductive and metabolic dysfunctions—in the absence of major disrup-
tions in the maternal/fetal steroid hormone milieu.
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